The 5th Middle East Best of CTRC-AACR San Antonio Breast Cancer Symposium
King Abdulaziz Medical City in cooperation with the Saudi Oncology Society (SOS) and the Arab Medical Association Against Cancer (AMAAC)
King Faisal Hall, InterContinental Hotel, Riyadh, Kingdom of Saudi Arabia
12-13 January 2011 |
|
DAY ONE (1) - 12 JANUARY 2011 - WEDNESDAY |
|
Time |
Topic |
Speaker(s) |
|
| |
|
|
0800 - 0850 |
Registration and Breakfast |
|
0850 - 0910 |
|
Dr. Omalkhair Abulkhair - Chairman, Scientific Committee
|
| |
. |
|
| |
The Clinical Utility with Genetic Testing for Inherited Predisposition to Breast Cancer: BRCA and Beyond |
Chairpersons:
Dr. Zahera Fahed
Dr. Salha Bujassoum |
| |
. |
|
|
0910 - 0940 |
Abstract # S4-8:
Promoter CpG Methylation of BRCA1 predicts for PARP inhibitors in breast cancer |
Dr. Arun Banu |
|
0940 - 1055 |
Update on Endocrine Therapy
|
Chairpersons:
Dr. Esam Murshid
Dr. Sami Khatib
Dr. Yaser Abdelkader |
| |
. |
|
0940 - 1055
|
Abstract # S1-1:
Final Analysis of NCIC CTG MA 27: A randomized phase III trial of Exemestane versus Anastrozole in postmenopausal women with hormone receptor positive primary breast cancer
|
|
|
|
Abstract # S1-2:
ACOSOG Z1031: A randomized neoadjuvant comparison between Letrozole (LET), Anastrozole (ANA), and Exemestane (EXE) for postmenopausal women with ER Rich stage 2/3 breast cancer: Biomarker outcomes and the predictive value of the baseline PAM50 based intri
|
|
|
|
Abstract # S1-3:
A comparison of Fulvestrant 500 mg with Anastrozole as first-line treatment for advanced breast cancer: Follow up analysis from the 'First' study
|
Dr. Melanie Royce |
|
|
Abstract # S1-4:
A randomized, placebo-controlled, phase II study of AMG 479 with Exemestane (E) or Fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) locally advanced (LA) or metastatic (M) breast cancer (BC)
|
Dr. Melanie Royce |
|
|
Abstract # S1-5:
Interaction between Goserelin and Tamoxifen in a controlled clinical trial of adjuvant endocrine therapy in premenopausal breast cancer
|
Dr. Melanie Royce |
|
1055 - 1115 |
Break |
|
1115 - 1200 |
Abstract # S1-6:
TAMRAD: A GINECO randomized phase II trial of everolimus in combination with Tamoxifen versus Tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to Aromatase inhibitors (AI)
|
Dr. Nagi Saghir |
|
|
Abstract # S1-7:
Lack of correlation between gene variants in Tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial
|
Dr. Nagi Saghir |
. |
|
Abstract # S1-8:
Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial
|
Dr. Nagi Saghir |
| |
. |
|
1200 - 1220 |
Abstract # S2-5:
Molecular profiling of aromatase inhibitor-treated post-menopausal breast tumors identifies determinants of response |
Dr. Alaa Kandil |
|
1220 - 1230 |
Discussion |
|
|
1230 - 1400 |
Lunch and Prayer and Poster Presentation Exhibition |
|
1455 -1555 |
|
Chairpersons:
Dr. Ahmed Saadeddin
Dr. Abdul Rahman Jazieh
Dr. Lobna Sedky
Dr. Mubarak Almansour
|
|
|
|
1400 - 1415 |
Abstract # S2-3:
The impact of body mass index (BMI) on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer (BC) patients; exploratory analysis from the TEAM study
|
Dr. Zeina Nahleh |
|
|
|
1415 - 1430 |
Abstract # S2-6:
Aromatase inhibitors and risk of myocardial infarction, stroke and fracture
|
Dr. Zeina Nahleh |
|
|
|
1430 - 1450 |
Abstract # S2-7:
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients
|
Dr. Hafez Halawani |
|
1450 - 1500 |
Discussion |
|
|
1500 - 1515 |
Abstract # S6-2:
313 patients with breast cancer during pregnancy: Results from a prospective and retrospective registry (GBG-20/BIG 02-03) |
Dr. Hamdy Azim |
|
. |
|
1515 - 1600 |
Abstract #:
Role of Media in Promoting Health |
Dr. Nadia Badawi |
|
. |
|
END OF THE FIRST DAY |
|
DAY TWO (2) - 13 JANUARY 2011 - THURSDAY |
|
Time |
Topic |
Speaker(s) |
|
0900 - 1015 |
Targeted Neoadjuvant Trials Update |
Chairpersons:
Dr. Adher Al Sayed
Dr. Ahmed Al Shehri |
| |
. |
|
0900 - 0945 |
Abstract # S3-1:
Lapatinib vs. Trastuzumab in combination with neoadjuvant Anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44)
|
Dr. Dennis Slamon |
|
|
Abstract # S3-2:
Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and safety analysis of a randomized phase II study ('Neosphere')
|
Dr. Dennis Slamon |
|
|
Abstract # S3-3:
First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of Lapatinib, Trastuzumab, and their combination plus Paclitaxel in women with HER 2-positive primary breast cancer
|
Dr. Dennis Slamon |
| |
|
|
0945 - 1000 |
Abstract # S4-6:
Neoadjuvant chemotherapy with or without Bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG44)
|
Dr. Deborah Armstrong |
|
|
|
1000 - 1015 |
GORG Study |
Dr. Taher Tweigeri |
|
1015 - 1025 |
Discussion |
|
|
1025 - 1040 |
Break |
|
|
1030 - 1245 |
|
Chairpersons:
Dr. Huda Abdulkareem
Dr. Abdulkareem Al-Momen |
|
|
|
1040 - 1055 |
Abstract # S4-1:
FinXX final 5-year analysis: Results of the randomized, open label, phase II trial in medium-to-high risk early breast cancer
|
Dr. Taher Tweigri |
|
|
|
1055 - 1110 |
Abstract # S4-2:
First efficacy results of a randomized, open label, phase II study of adjuvant Doxorubicin plus Cyclophosphamide followed by Docetaxel with or without Capecitabine in high-risk early breast cancer
|
Dr. Taher Tweigri |
|
|
|
1110 - 1125 |
Abstract # S4-3:
Ten-year follow-up analysis of the BICRG 001 trial confirms superior DFS and OS benefit of adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (Fluorouracil, Doxorubicin, Cyclophosphamide) in women with operable nodepositive breast cancer
|
Dr. Taher Tweigri |
|
|
|
1130 - 1145 |
Abstract # S4-5:
Adjuvant treatment with Zoledronic Acid in stage II/II breast cancer. The AZURE Trial (BIG 01/04)
|
Dr. Sana Sukhun |
|
1145 - 1200 |
Discussion |
|
|
1345 - 1515 |
|
Chairpersons:
Dr. Shabanah Mohamad
Dr. Abdulrahman Hadab |
| |
|
|
1200 - 1220 |
Radio Surgery and Stereotactic Body Radiotherapy
|
Dr. Fady Geara |
|
1220 - 1230 |
Discussion |
|
|
1230 - 1330 |
Lunch and Prayer and Poster Presentation Exhibit |
|
1330 - 1430 |
Challenges in Breast Cancer Management
|
Chairpersons:
Dr. Omalkhair Abulkhair
Dr. Dahish Ajarim
Dr. Hamdy Azim
|
|
|
|
1430 - 1445 |
Abstract # S6-6:
High independent prognostic and predictive value of circulating tumor cells in a large prospective multicenter trial including serum tumor markers in first line chemotherapy metastatic breast patients |
Dr. Deborah Armstrong |
| |
. |
|
1445 - 1500 |
Cancer Micrometastasis and Circulating Tumor Cells
|
Dr. Deborah Armstrong |
| |
. |
|
1500 - 1545 |
Abstracts from the Middle East |
Dr. Omalkhair Abulkhair
Dr. Ali Shanqeeti
Dr. Abdulmohsen Kushi
Dr. Taher Tweigeri
Dr. Hamdy Azim
Dr. Abdulaziz Al Saif
Dr. Abdulrahman Hadab |
| |
. |
|
| |
Poster Selection |
Dr. Esam Murshid
Dr. Ali Zahrani
Dr. Bazar Bashi
Dr. Khalid Balaraj
Dr. Deborah Armstrong
Dr. Melanie Royce |
|
1545 - 1600 |
Closing Remarks and Awarding of Prizes for the Best Abstracts
|
|
| |
|
|
END OF THE SYMPOSIUM |
|
